Abstract

Background: Hyperuricemia is known to be associated with cardiovascular complications. However, there are limited data whether there is a clear association between hyperuricemia and long-term clinical outcomes of patients (pts) undergoing percutaneous coronary intervention (PCI) in drug-eluting stents (DESs) era.

Methods: This study consisted of 1,668 consecutive pts underwent PCI with DESs from January 2004 to August 2010. Twelve-month cumulative clinical outcomes were compared between the hyperuricemia group (Uric acid ≥7mg/dL, n=229) and the Control group (Uric acid <7mg/dL, n=1,439).

Results: The baseline clinical characteristics showed that hyperuricemia group had more elderly, male gender, cardiogenic shock, hypertension, peripheral artery disease and lower left ventricular ejection fraction (LVEF). The hyperuricemia group showed higher cumulative incidence of cardiac death, Q-wave myocardial infarction, target lesion and vessel-major adverse cardiac events (MACEs) and stent thrombosis up to 2 years (Table). Multivariate analysis showed that hyperuricemia was an independent predictor of cardiac death (Adjust OR: 3.896, 95% CI: 2.038-7.445, p<0.001) and target vessel revascularization (TVR)-MACE (Adjust OR: 1.769, 95% CI: 1.168-2.674, p=0.007).

View larger version:

• In this page
 
• In a new window

• Download as PowerPoint Slide

Conclusion: Hyperuricemia was associated with higher incidence of cardiac death, MACE and stent trombosis up to 2 years and may play an important role in predicting long term clinical outcomes in pts undergoing PCI in DES era.